公开(公告)号：US5994090A

公开(公告)日：1999-11-30

申请号：US750677

申请日：1996-12-03

申请人： Kazuhiro Matsuda ,  Naoki Yamamoto

发明人： Kazuhiro Matsuda ,  Naoki Yamamoto

IPC分类号： G01N33/92 ,  C07H15/04 ,  C07H15/06 ,  C07H15/10 ,  C07K16/00 ,  C07K16/12 ,  C07K16/44 ,  C12N15/02 ,  C12P19/04 ,  C12P19/44 ,  C12P21/08 ,  C12R1/91 ,  G01N33/569 ,  G01N33/554 ,  A61K39/02 ,  C07H5/04 ,  C12Q1/32

CPC分类号： C07H15/06 ,  C07H15/10 ,  C07K16/1253 ,  C12P19/44 ,  G01N33/56933

摘要： Mouse is immunized with an antigen of a lipid fraction originating from Mycoplasma fermentans. Its spleen cells are fused with mouse myeloma cells to prepare hybridomas. A hybridoma is selected, which produces a monoclonal antibody having reaction specificity to GGPL-III that is a phosphocholine-containing glycoglycerolipid specific to Mycolplasma fermentans. Mycoplasma fermentans is detected by using the obtained antibody.

摘要翻译： PCT No.PCT / JP95 / 01091 Sec。 371日期1996年12月3日第 102（e）日期1996年12月3日PCT归档1995年6月2日PCT公布。 出版物WO95 / 33758 1995年12月14日，小鼠用来自发酵支原体的脂质部分的抗原免疫。 将其脾细胞与小鼠骨髓瘤细胞融合以制备杂交瘤。 选择杂交瘤，其产生对GGPL-III具有反应特异性的单克隆抗体，GGPL-III是对发酵酵母菌特异性的含磷酸胆碱的甘油糖脂。 通过使用获得的抗体检测发酵支原体。

公开(公告)号：US5948692A

公开(公告)日：1999-09-07

申请号：US687406

申请日：1996-08-02

申请人： Satoshi Miyauti ,  Katuyuki Horie

发明人： Satoshi Miyauti ,  Katuyuki Horie

IPC分类号： G01N33/564 ,  G01N33/68 ,  G01N33/53 ,  G01N33/566

CPC分类号： G01N33/564 ,  G01N33/6887 ,  G01N33/6893 ,  G01N2333/4722 ,  G01N2800/102

摘要： A method of assaying normal aglycans and an assaying kit therefor, which method comprises separating normal aglycans having an avidity for hyaluronic acid and present in a specimen from proteoglycans not having such an avidity and detecting only the normal aglycans. The separated normal aglycans are detected by the technique of detecting proteoglycans. The specimen is preferably a joint fluid originating in the joint as the target of judgement. A method of judging joint-related information comprises detecting information on the amount of normal aglycans in a specimen and the total amount of proteoglycans therein with the above method and kit, comparing the obtained information with the same type of information, which has been prepared in advance, on the amounts of the above-specified compounds in a joint fluid originating in a normal joint, and judging whether the obtained information is one pertinent to pathologic joints or one pertinent to normal joints on the basis of the presence or absence of any significant difference therebetween. The information pertinent to pathologic joints is classified into the one pertinent to arthrosis deformans, the one pertinent to rheumatoid arthritis, the one pertinent to traumatic arthritis, and the one pertinent to gout. The method and kit can be utilized for the biochemical diagnosis of joint diseases in the field of orthopedics. They can be utilized also for discriminating normal joints from pathologic joints, for grasping morbidity such as judgement on the type and prognosis of joint diseases, and for grasping the curative effects by determining the concentration of normal aglycan, the content of normal aglicans in the whole of proteoglycans, and so forth.

公开(公告)号：US5939403A

公开(公告)日：1999-08-17

申请号：US849925

申请日：1997-06-02

申请人： Hiroshi Maruyama ,  Kiyoshi Morikawa ,  Akira Tawada ,  Satoshi Miyauchi ,  Keiichi Yoshida ,  Akira Asari

发明人： Hiroshi Maruyama ,  Kiyoshi Morikawa ,  Akira Tawada ,  Satoshi Miyauchi ,  Keiichi Yoshida ,  Akira Asari

IPC分类号： A61K31/737 ,  C07H11/00 ,  C07H13/04 ,  C08B37/00 ,  C12P19/26 ,  A61K31/73 ,  A61K31/725 ,  C08B3/04 ,  C08B3/06

CPC分类号： A61K31/7024 ,  A61K31/702 ,  A61K31/737 ,  C07H11/00 ,  C07H13/04 ,  C08B37/0063 ,  C12P19/26 ,  Y10S514/885

摘要： A keratan sulfate oligosaccharide which comprises from two to five sugar units and has sulfated N-acetylglucosamine at the reducing end and in a molecule of which at least two hydroxyl groups are sulfated, preferably, which contains at least disaccharide represented by the formula Gal(6S)-GlcNAc(6S) (in the formula, Gal, GlcN, Ac, and 6S represent a galactose, a glucosamine, an acetyl group, and a 6-O-sulfate ester, respectively) as a constitutional ingredient, and/or pharmaceutically acceptable salt thereof are used as active ingredients of anti-inflammatory agents, antiallergic agents, immunomodulators, cell differentiation inducers, and apoptosis inducers.

摘要翻译： PCT No.PCT / JP95 / 02386 Sec。 371日期：1997年6月2日 102（e）日期1997年6月2日PCT提交1995年11月22日PCT公布。 公开号WO96 / 16973 日期：1996年6月6日硫酸角质素寡糖，其包含2至5个糖单元并且在还原端具有硫酸化的N-乙酰葡糖胺，并且其至少两个羟基被硫酸化的分子中，优选至少含有由 配方Gal（6S）-GlcNAc（6S）（在分子式中，Gal，GlcN，Ac和6S分别代表半乳糖，葡糖胺，乙酰基和6-O-硫酸酯）作为构成成分 ，和/或其药学上可接受的盐用作抗炎剂，抗过敏剂，免疫调节剂，细胞分化诱导剂和凋亡诱导剂的活性成分。

公开(公告)号：US5840510A

公开(公告)日：1998-11-24

申请号：US885176

申请日：1997-06-30

申请人： Shigenori Tanaka ,  Hiroshi Tamura ,  Kazuhiro Aita

发明人： Shigenori Tanaka ,  Hiroshi Tamura ,  Kazuhiro Aita

IPC分类号： G01N33/543 ,  G01N33/579 ,  C12Q1/37 ,  C12Q1/00 ,  C12Q1/34 ,  C12Q1/56

CPC分类号： G01N33/579 ,  G01N2333/811 ,  Y10S435/967

摘要： This invention provides (1) a reagent for endotoxin assay which comprises aprotinin and a limulus amebocyte lysate reagent, (2) a kit for endotoxin assay which comprises the limulus amebocyte lysate reagent and a reagent containing aprotinin, (3) a method for assaying endotoxin in a sample using the limulus amebocyte lysate reagent in which aprotinin is added to the lysate reagent and/or the sample, (4) a method for assaying endotoxin in a serine protease-containing sample using the limulus amebocyte lysate reagent in which the sample is allowed to contact with an aprotinin-immobilized insoluble carrier in advance of endotoxin assay, (5) a carrier for pretreating a serine protease-containing sample on which aprotinin is immobilized, (6) a method for inhibiting factor G activation in which aprotinin is added to the limulus amebocyte lysate reagent and (7) a factor G activation inhibitor which comprises aprotinin as an active ingredient. Endotoxin assay can be effected based on the factor C system reaction, without influences of factor G contained in the limulus amebocyte lysate reagent and/or serine proteases contained in samples.

摘要翻译： 本发明提供（1）含有抑肽酶和鲎变形细胞裂解物试剂的内毒素试剂，（2）包含鲎变形细胞裂解物试剂和含有抑肽酶的试剂的内毒素试剂盒，（3）检测内毒素的方法 在使用鲎变形细胞裂解物试剂的样品中，其中将抑肽酶加入到裂解物试剂和/或样品中，（4）使用鲎变形细胞裂解物试剂测定含丝氨酸蛋白酶样品中的内毒素的方法，其中样品是 在内毒素测定之前允许与抑肽酶固定的不溶性载体接触，（5）用于预处理含有抑肽酶的丝氨酸蛋白酶的样品的载体，（6）抑制因子G激活的方法，其中加入抑肽酶 到鲎变形细胞裂解物试剂和（7）包含抑肽酶作为活性成分的因子G激活抑制剂。 内毒素测定可以基于因子C系统反应进行，而不受样品中包含的鲎变形细胞裂解物试剂和/或丝氨酸蛋白酶中所含因子G的影响。

公开(公告)号：US5776899A

公开(公告)日：1998-07-07

申请号：US454235

申请日：1995-06-13

申请人： Akiyoshi Matsumoto ,  Michinori Waki

发明人： Akiyoshi Matsumoto ,  Michinori Waki

IPC分类号： A61K38/00 ,  A61K38/10 ,  A61P31/12 ,  C07K7/08 ,  C07K14/435 ,  A61K38/04 ,  C07K5/00 ,  C07K7/00

CPC分类号： C07K7/08 ,  A61K38/00

摘要： A polypeptide represented by formula (I), and one example of such polypeptide be represented as formula 1 is presented. The above presented polypeptide may be useful in a pharmaceutical composition as an antimicrobial or antiviral agent, specifically as an anti-HIV agent and as a component of the DNA-transfecting systems for gene therapy.

摘要翻译： PCT No.PCT / JP94 / 01706 Sec。 371日期：1995年6月13日 102（e）日期1995年6月13日PCT 1994年10月12日PCT PCT。 公开号WO95 / 10534 日期：1995年04月20日（一）由式（I）表示的多肽和该多肽的一个实例表示为式1。 上述多肽可用作药物组合物中的抗微生物剂或抗病毒剂，特别是抗HIV剂，以及用作基因治疗的DNA转染系统的组分。

公开(公告)号：US5496718A

公开(公告)日：1996-03-05

申请号：US082853

申请日：1993-06-23

申请人： Nobukazu Hashimoto ,  Hideo Mochizuki ,  Akio Hamai

发明人： Nobukazu Hashimoto ,  Hideo Mochizuki ,  Akio Hamai

IPC分类号： A61K38/43 ,  A61K38/00 ,  C12N9/16 ,  C12N9/20 ,  C12N9/88 ,  C01G17/04 ,  C12N1/12

CPC分类号： C12N9/88 ,  A61K38/00 ,  G03C2001/0471 ,  Y10S435/873

摘要： A crystallizable, purified chondroitinase ABC having a molecular weight of about 100,000 dalton by the measurement of the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and the measurement by the gel permeation chromatography method, having alanine as the N-terminal amino acid and proline as the C-terminal amino acid. A process for the purification of the crystallizable purified chondroitinase ABC comprising removing nucleic acid from an surfactant solution extract obtained from cells of chondroitinase ABC-producing microorganisms and chromatographically treating by concentration gradient elution using a weak cation exchange resin or a strong cation exchange resin. A composition comprising a chondroitinase and serum albumin, gelatin, or a nonionic surfactant. The chondroitinase ABC is isolated from Proteus vulgaris ATCC 6896.

摘要翻译： 通过SDS-聚丙烯酰胺凝胶电泳（SDS-PAGE）的测量和通过凝胶渗透色谱法测定的具有约100,000道尔顿分子量的可结晶纯化的软骨素酶ABC，其具有丙氨酸作为N-末端氨基酸和脯氨酸 作为C末端氨基酸。 一种用于纯化可结晶的纯化软骨素酶ABC的方法，包括从获自软骨素酶ABC微生物的细胞获得的表面活性剂溶液提取物中除去核酸，并使用弱阳离子交换树脂或强阳离子交换树脂进行色谱法处理。 包含软骨素酶和血清白蛋白，明胶或非离子表面活性剂的组合物。 软骨素酶ABC从普通变形杆菌ATCC 6896中分离。

公开(公告)号：US5286625A

公开(公告)日：1994-02-15

申请号：US789583

申请日：1991-11-08

申请人： Shigenori Tanaka ,  Hiroshi Tamura

发明人： Shigenori Tanaka ,  Hiroshi Tamura

IPC分类号： G01N33/579 ,  C12Q1/34 ,  C12Q1/00 ,  C12Q1/37 ,  G01N1/00

CPC分类号： G01N33/579 ,  Y10T436/25125

摘要： A method of assaying an endotoxin using the limulus amebocyte lysate component which comprises pretreating whole blood with nitric acid and a surfactant selected from among polyoxyethylene ethers represented by the following formula: ##STR1## wherein n is an integer of from 8 to 40; or: ##STR2## polyoxyethylene sorbitans, n-alkylglucopyranosides, sodium dodecylsulfate and lithium dodecylsulfate, which enables an efficient and accuate assay of an endotoxin.

摘要翻译： 使用鲎变形细胞裂解物成分测定内毒素的方法，其包括用硝酸预处理全血和选自下式表示的聚氧乙烯醚中的表面活性剂：（*化学结构*）其中n为8〜40的整数 ; 或：（*化学结构*）聚氧乙烯脱水山梨糖醇酐，正烷基吡喃糖苷，十二烷基硫酸钠和十二烷基硫酸钠，其能够有效地进行内毒素测定。

公开(公告)号：US11779593B2

公开(公告)日：2023-10-10

申请号：US17509576

申请日：2021-10-25

申请人： SEIKAGAKU CORPORATION

发明人： Masamichi Yamada ,  Chiyo Sakenaga ,  Keiichiro Arai ,  Kazutaka Yamamoto

IPC分类号： A61K31/728 ,  A61K9/08 ,  A61P27/04 ,  A61P27/02 ,  A61K9/00

CPC分类号： A61K31/728 ,  A61K9/0048 ,  A61K9/08 ,  A61P27/02 ,  A61P27/04

摘要： Provided is an agent for improving human ocular subjective symptoms containing hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto.

公开(公告)号：US20230263871A1

公开(公告)日：2023-08-24

申请号：US18133168

申请日：2023-04-11

申请人： SEIKAGAKU CORPORATION

发明人： Mine HIGUCHI

IPC分类号： A61K38/51 ,  A61K9/19

CPC分类号： A61K38/51 ,  A61K9/19 ,  C12Y402/02004

摘要： A pharmaceutical composition containing a lyophilized saccharide-degrading enzyme having excellent titer, and a package containing the pharmaceutical composition. The pharmaceutical composition is a unit dose formulation containing a lyophilized saccharide-degrading enzyme with a titer of not less than 0.3 unit/μg as an active ingredient, and contains the saccharide-degrading enzyme in an amount of not less than 2 μg and not more than 6 μg.

公开(公告)号：US11499177B2

公开(公告)日：2022-11-15

申请号：US16490100

申请日：2018-03-01

申请人： SEIKAGAKU CORPORATION

发明人： Yuki Kobayashi ,  Hikaru Mizumura ,  Toshio Oda ,  Shun-Ichiro Kawabata

IPC分类号： C12Q1/37 ,  C12N9/50

摘要： Provided is a technology related to a horseshoe crab factor B variant, and also provided is means for performing endotoxin measurement with high sensitivity. A polypeptide having an amino acid sequence in which the amino acid residue at the 193-position in an amino acid sequence of a polypeptide of horseshoe crab factor B is substituted with a cysteine (Cys) residue, is produced. Endotoxin measurement can be carried out with high sensitivity by configuring a Limulus reagent by combining this polypeptide with horseshoe crab factor C.